News Archive

Epstein Becker Green Forms Collaboration with Data, Social Scientists for AI Consulting

Bradley Merrill Thompson Quoted in “Ready or Not, AI Chatbots Are Coming to Hospitals”

Bradley Merrill Thompson Quoted in “FDA Draft Guidance Allows AI/ML Devices to Evolve Without Requiring New Submissions”

Bradley Merrill Thompson Quoted in “FDA Draft Guidance for AI Change Control Shifts Workload to Initial Premarket Filing”

Insulin as Preventive Care: Why Not Eliminate Patient Cost Sharing?

Richard Hughes, Spreeha Choudhury Featured in “Loosening Restrictions on Pharmacists Could Help Raise Children’s Vaccination Rates”

Bradley Merrill Thompson Quoted in “Growth of AI in Mental Health Raises Fears of Its Ability to Run Wild”

Bradley Merrill Thompson Quoted in “The FDA Plans to Regulate Far More AI Tools as Devices. The Industry Won’t Go Down Without a Fight”

Bradley Merrill Thompson Quoted in “Why Congress Quietly Just Gave the FDA More Power”

Bradley Merrill Thompson Quoted in “NIST Releases New AI Risk Management Framework for ‘Trustworthy’ AI”

James Boiani, Bradley Merrill Thompson Quoted in “And Over at FDA …”

Clifford Barnes Featured in Follow the Brand Podcast: “Wise Counsel”

Bradley Merrill Thompson Quoted in “Outlook 2023: The Regulatory Path Ahead”

Leslie Norwalk Featured in Her Story Podcast: “Continue to Be Curious”

Bradley Merrill Thompson Quoted in “Torres Says Regulatory Alignment a Pressing Consideration for AI Change Control Draft”

Bradley Merrill Thompson Quoted in “Software to Predict Risk of Sepsis, Stroke Should Be Regulated as a Medical Device, Says FDA”

Bradley Merrill Thompson Quoted in “FDA Acknowledges Shortcomings of Pre-Cert Pilot in Report”

Bradley Merrill Thompson Quoted in “A ‘Disaster,’ or a ‘Clear Path’ Forward?: New FDA Guidance on AI in Medicine Sparks Strong Reactions”

Bradley Merrill Thompson Quoted in “FDA Talks Takeaways from Software Precert Pilot”

Bradley Merrill Thompson Mentioned in “FDA Draft for Digital Tech in Clinical Trials Languishes Despite Agency’s Digital Push”

Epstein Becker Green’s Unpacking Averages Report “Casts Doubt on Value of US FDA’s Breakthrough Devices Program”

Philo Hall Quoted in “Puerto Rico: The ‘Canary in the Coal Mine’ for Medicare Advantage Growth”

Richard Hughes’ Article on Immunization Access Cited in “A Twenty-First Century 'Vaccines for Children' Program”

Bradley Merrill Thompson Quoted in “Senate HELP Sends User Fee Reauthorization Bill to Floor Vote”

Bradley Merrill Thompson Quoted in “FDA Should Step In to Help Spur AI/ML Standards”

Bradley Merrill Thompson Quoted in “FDA Ends Pre-Cert but Could Revisit in the Future, with Congress’ Help”

Bradley Merrill Thompson Quoted in “Racial Equity Increasing in Device Trials, but Reporting Remains Low”

Bradley Merrill Thompson Quoted in “3 Key FDA Topics for Medtechs in 2022”

Bradley Merrill Thompson Mentioned in “FDA Combo Products Guidance Offers More Flexibility for Cross-Labeling”

Bradley Merrill Thompson Quoted in “Use This App and Call Me in the Morning: The Promise of Prescription Digital Therapeutics”

Bradley Merrill Thompson Quoted in “Top Med-Tech Trends of 2021: Regulatory Torpor Adding Drag to Advances in Artificial Intelligence, Machine Learning”

Bradley Merrill Thompson Quoted in “After the Buzz, AI Finding Its Place in Health Care”

Kevin Malone Quoted in “Employers on Hook for Mental Health Parity Despite New Target”

Bradley Merrill Thompson Quoted in “FDA Regulation of AI Complicated by Hospital’s Use of In-House Algorithms”

Bradley Merrill Thompson Quoted in “FDA Promises a Draft Guidance for Change Control for Artificial Intelligence in 2021”